Walking Ability Study in Young Children With NF1
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study looks at how young children with neurofibromatosis type 1 (NF1)—a genetic condition affecting nerve growth—walk and move. Understanding gait patterns may help doctors better support children's development and physical health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has been diagnosed with NF1 (neurofibromatosis type 1) according to standard medical criteria
- Your child is able to walk independently without assistance
- Your child is 71 months old or younger (about 5 years 11 months)
- You are the parent or legal guardian and can provide informed consent
- Your child does not have other medical conditions that significantly affect movement or nerve function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study talks with people who have NF1 (and caregivers of children with NF1) about how visible tumors affect them. The goal is to create questionnaires that measure these concerns, which could lead to better support and treatments.
This study looks for better ways to measure how much tumor activity people with neurofibromatosis type 1 (NF1) have over time. The goal is to develop “biomarkers,” which are test results that may help doctors track disease more easily.
This study uses special MRI scans plus computer (AI) analysis to look for early, possibly cancer-related skin or tissue changes in children with neurofibromatosis type 1 (NF1). If it works, it could help doctors detect concerning changes earlier and plan care sooner.
This study looks at how children with FSHD move and function over time. It uses walking tests and optional MRI scans to understand muscle changes. Your child's participation could help researchers learn more about FSHD progression in kids.
This study looks at how children and teens with Duchenne muscular dystrophy (DMD) or spinal muscular atrophy (SMA) walk, by having them do walking tests while wearing sensors. The goal is to find better ways to track how these diseases progress and how treatments work over time, without needing blood tests or scans.
This study tracks people with NF1 to watch for when benign nerve tumors turn cancerous. It uses regular MRI scans to catch changes early, which could help guide treatment decisions.
Hear when a new Neurofibromatosis Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.